UNG and cancer: Outside of the cancer field, DNA glycosylase inhibition is most likely to find its soonest clinical application in antiviral therapy, since two important groups of human pathogens, poxviruses and herpesviruses, possess their own uracil-DNA glycosylases, a validated target required for replication in host cells, and several promising drug leads are available.